Compare YHC & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | YHC | QNCX |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 19.9M |
| IPO Year | N/A | 2019 |
| Metric | YHC | QNCX |
|---|---|---|
| Price | $0.78 | $0.93 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 388.7K | ★ 1.4M |
| Earning Date | 04-15-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.88 |
| Revenue | N/A | N/A |
| Revenue This Year | $1,267.57 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.33 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.50 | $0.08 |
| 52 Week High | $11.14 | $4.55 |
| Indicator | YHC | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 42.42 | 41.03 |
| Support Level | $0.76 | $0.79 |
| Resistance Level | $1.03 | $0.98 |
| Average True Range (ATR) | 0.13 | 0.09 |
| MACD | -0.01 | -0.03 |
| Stochastic Oscillator | 41.07 | 12.79 |
LQR House Inc intends to become the full-service digital marketing and brand development face of the alcoholic beverage space. It also intends to integrate the supply, sales, and marketing facets of the alcoholic beverage space into one easy-to-use platform and become the one-stop shop for everything related to alcohol. The company's primary business includes the development of premium limited-batch spirit brands, establishing an exclusive wine club, and marketing internal and external brands through an exclusive agreement with a United States-based e-commerce portal. It believes that the marketing and brand management services it provides to its wholly owned and third-party clients will increase brand recognition, and drive sales thereof through its e-commerce platform partner.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.